SequelSEC

OnKure Therapeutics, Inc. OKUR

Pharmaceutical Preparations · CIK 0001637715 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$54.39M
Fiscal year ended 2024-12-31
Free cash flow
-$51.17M
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$28.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.05Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio10.73x81th

OnKure Therapeutics, Inc. (OKUR) reported revenue of $0 and net income of -$52.67M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from OnKure Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

OnKure Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$54.39M
Net income-$52.67M
Research & development$43.80M
Weighted-average diluted sharesshares 3.45M
Pretax incomeUnavailable
Income tax expense$0
Diluted EPS$-15.28
Selling, general & administrativeUnavailable
General & administrative$10.59M
Selling & marketingUnavailable

Balance

OnKure Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$110.76M
Total assets$114.91M
Current assets$113.00M
Total liabilities$11.08M
Current liabilities$10.53M
Total equity incl. NCI$103.83M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.97M

Cash flow

OnKure Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow-$51.12M
Capital expenditures$52.00K
Investing cash flow$15.87M
Financing cash flow$116.13M
Net change in cash$80.88M
Stock-based compensation$4.53M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$459.00K

Derived

OnKure Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flow-$51.17M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio10.73x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OKUR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.